| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 105.582 | 64.670 | 13.827 | 8.330 | 13.831 | 22.525 | 25.796 | 27.617 | 28.335 | 28.507 |
| Total Income - EUR | 138.571 | 67.177 | 13.827 | 8.330 | 13.831 | 22.525 | 26.474 | 27.617 | 47.022 | 34.217 |
| Total Expenses - EUR | 135.722 | 66.115 | 17.522 | 11.713 | 14.847 | 16.822 | 23.315 | 23.423 | 26.327 | 27.800 |
| Gross Profit/Loss - EUR | 2.849 | 1.063 | -3.695 | -3.383 | -1.015 | 5.703 | 3.158 | 4.193 | 20.695 | 6.417 |
| Net Profit/Loss - EUR | 2.849 | 1.063 | -4.047 | -3.633 | -1.430 | 5.049 | 2.364 | 3.365 | 17.816 | 6.126 |
| Employees | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Pharma Bios S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 14.378 | 15.413 | 14.835 | 14.252 | 13.671 | 13.212 | 12.919 | 12.960 | 9.203 | 9.152 |
| Current Assets | 105.359 | 45.194 | 36.981 | 27.427 | 24.998 | 17.201 | 19.848 | 11.616 | 36.711 | 25.045 |
| Inventories | 76.284 | 33.212 | 20.212 | 9.544 | 6.300 | 4.275 | 10.430 | 3.338 | 16.544 | 8.436 |
| Receivables | 17.590 | 11.098 | 16.066 | 16.910 | 16.625 | 8.924 | 3.638 | 2.966 | 4.924 | 9.794 |
| Cash | 11.485 | 885 | 703 | 973 | 2.073 | 4.002 | 5.781 | 5.312 | 15.243 | 6.815 |
| Shareholders Funds | -4.280 | -3.174 | -7.167 | -10.669 | -11.892 | -8.060 | -5.518 | -2.170 | 15.652 | 7.706 |
| Social Capital | 47 | 47 | 46 | 45 | 44 | 43 | 42 | 43 | 42 | 42 |
| Debts | 124.017 | 63.781 | 58.983 | 52.347 | 50.562 | 38.474 | 38.285 | 26.745 | 30.262 | 26.491 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Pharma Bios S.r.l.